Century Therapeutics (NASDAQ:IPSC – Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.12) per share and revenue of $1.63 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 17, 2026 at 9:30 AM ET.
Century Therapeutics (NASDAQ:IPSC – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). On average, analysts expect Century Therapeutics to post ($0.51) EPS for the current fiscal year and ($0.51) EPS for the next fiscal year.
Century Therapeutics Stock Down 7.2%
IPSC opened at $1.68 on Wednesday. Century Therapeutics has a 12-month low of $0.43 and a 12-month high of $3.04. The stock’s 50 day moving average price is $1.67 and its two-hundred day moving average price is $2.08. The firm has a market capitalization of $304.20 million, a P/E ratio of -1.81 and a beta of 1.78.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on Century Therapeutics
Century Therapeutics Company Profile
Century Therapeutics, Inc. is a biotechnology company focused on developing allogeneic, or “off-the-shelf,” cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create immune-effector cells, including natural killer (NK) cells and T cells, that can be engineered to recognize and attack tumor cells. Century’s pipeline has included product candidates designed for hematologic malignancies and solid tumors. Its programs incorporate technologies intended to improve the persistence, activity, and scalability of engineered immune cells, with development efforts involving targets such as CD19 and other tumor-associated antigens.
Read More
- Five stocks we like better than Century Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
